PerkinElmer to acquire Caliper Life Sciences for $600M
PerkinElmer has signed a definitive agreement to acquire Caliper Life Sciences of Hopkinton, Mass., for approximately $600 million.
Waltham, Mass.-based PerkinElmer said in a release that the acquisition received the unanimous support of the boards of directors of both companies. It is expected to close in the fourth quarter this year.
The transaction is subject to customary closing conditions, including approval of Caliper Life Sciences stockholders, and the expiration or termination of a mandated waiting period.
Caliper Life Sciences develops products and services for the pharmaceutical and biotechnology research community. Its CEO, Kevin Hrusovsky, is anticipated to join the PerkinElmer senior leadership team following the close of the transaction, according to the release.
Waltham, Mass.-based PerkinElmer said in a release that the acquisition received the unanimous support of the boards of directors of both companies. It is expected to close in the fourth quarter this year.
The transaction is subject to customary closing conditions, including approval of Caliper Life Sciences stockholders, and the expiration or termination of a mandated waiting period.
Caliper Life Sciences develops products and services for the pharmaceutical and biotechnology research community. Its CEO, Kevin Hrusovsky, is anticipated to join the PerkinElmer senior leadership team following the close of the transaction, according to the release.
Evan Godt, Writer
Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.